ATAI | Investor Presentation Deck | 33 slides

atai Life Sciences · 2023-02
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON

Slide inventory

33
every slide · same image gating as the playbook
01
Slide 1
front_matter
02
Includes a date note at the bottom: 'Note: Unless otherwise stated, this presentation is as of January 6th, 2023'other
03
The slide uses a numbered list to present five key pillars of the company's value proposition.summarize
Open slide detailLoop · Golden Circle
04
The slide uses a hierarchical structure to connect a high-level objective to three specific operational pillars.present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
05
The slide uses a Gantt-style visualization to represent drug development stages.plan_implementation
Open slide detailBeat · SolutionLoop · Golden Circle
06
The slide combines a historical achievement list with a forward-looking roadmap and financial runway statement.plan_implementation
Open slide detailBeat · SolutionLoop · Golden Circle
07
transition
Open slide detailBeat · SolutionLoop · Golden Circle
08
Uses a timeline-style visual to represent the 'need' metrics.frame_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
09
The slide uses a bar chart to show dose-dependent efficacy across three cognitive tests (HVLT, Symbol Coding, Category Fluency).summarize
Open slide detailBeat · ProblemLoop · Cost Of Inaction
10
The slide uses a vertical process flow to demonstrate the de-risking of the drug candidate.present_solution
Open slide detailBeat · TractionLoop · Golden Circle
11
The slide highlights the efficacy of RL-007 in cognitive endpoints during a Phase 2 study.show_traction
Open slide detailBeat · TractionLoop · Golden Circle
12
The slide uses a standard clinical trial flow diagram to illustrate the study protocol.present_framework
Open slide detailBeat · TractionLoop · Golden Circle
13
The slide uses a feature-comparison matrix to highlight the competitive advantage of RL-007.compare_peers
Open slide detailBeat · Competitive AnalysisLoop · Golden Circle
14
transition
Open slide detailBeat · Competitive AnalysisLoop · Golden Circle
15
The slide uses a dual-column layout: left side establishes the scale of the problem (market sizing/context), right side details the clinical pain points.frame_problem
Open slide detailLoop · Golden Circle
16
The slide uses a line chart to demonstrate the efficacy of different dosages of COMP360 over 12 weeks.show_traction
Open slide detailLoop · Golden Circle
17
The slide uses a timeline-based process diagram to illustrate clinical trial protocols.plan_implementation
Open slide detailLoop · Golden Circle
18
The slide uses a split layout: a left-hand sidebar for product summary and a right-hand side for clinical data visualization.summarize
Open slide detailLoop · Golden Circle
19
The slide uses a dark sidebar for product specs and a white main area for trial design and results.summarize
Open slide detailLoop · Golden Circle
20
transition
Open slide detailLoop · Golden Circle
21
The slide uses a combination of a disease overview, a map-based infographic, and a vertical timeline-style list to highlight the market opportunity.frame_problem
Open slide detailLoop · Golden Circle
22
The slide uses a split-layout with a left-hand summary table and a right-hand clinical data visualization.summarize
Open slide detailLoop · Golden Circle
23
The slide uses a numbered list to highlight key safety findings alongside a detailed data table.analyze_data
Open slide detailLoop · Golden Circle
24
The slide uses topographical brain maps to visualize EEG data changes across three cohorts.analyze_data
Open slide detailLoop · Golden Circle
25
The chart uses error bars and statistical significance markers (asterisks) to compare dose groups against a zero baseline.analyze_data
Open slide detailLoop · Golden Circle
26
The table uses checkmarks to indicate positive attributes across different drug classes.compare_peers
Open slide detailLoop · Golden Circle
27
transition
Open slide detailLoop · Golden Circle
28
Uses a timeline-style visual to list key statistics about the OUD crisis.frame_problem
Open slide detailLoop · Golden Circle
29
The slide uses a split-layout: a left-hand sidebar for company/product facts and a right-hand main area for clinical data and trial design.summarize
Open slide detailLoop · Golden Circle
30
The slide uses a feature-comparison matrix to highlight the unique value proposition of DMX-1002 (Ibogaine) against standard MAT and withdrawal support drugs.compare_peers
Open slide detailLoop · Golden Circle
31
transition
Open slide detailLoop · Golden Circle
32
present_solution
Open slide detailLoop · Golden Circle
33
The slide uses a personal narrative to establish the 'why' behind the company's mission.inspire_vision
Open slide detailLoop · Golden Circle